1Mikuls T, Moreland L.Predicting outcomes in early rheumatoid arthritis. Curr Rheumatol Rep,2002,4:193-194.
2Mullan RH, Bresnihan B. Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis.Clin Exp Rheumatol,2003,21(5Suppl31):S158-164.
4American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum,2002,46:328-346.
二级参考文献11
1Amer EC,Harris RR,Dimeo TM,et al. Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit.J Rheumatol,1995,22:1338-1346.
2Pelletier JP, Caron JP, Evans CH,et al.In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum,1997,40:1020-1019.
3Makarov SS,Olsen JC,Johnston WN,et al.Suppression of experimentlal arthritis by gene transfer of interleukin-1 receptor antagonist cDNA.Proc Natl Acad Sci USA,1996,93:402-406.
4Goater J,Muller R,Kollias G,et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis.J Rheumatol,2000,27:983-989.
5Smith MD,Triantafillou S,Parker A,et al.Synovial membrane inflammation and cytokine production in patients with early osteoarthritis.J Rheumatol, 1997,24:365-371.
6Sanshiro H,Kenji T,David A,et al. Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis.Arthritis Rheum, 1998,41:1266-1274.
7Otani K,Nita I,Macaulay W,et al. Suppression of antigen-induced arthritis by gene therapy.J Immunol, 1996,156:3558-3562.
8Fernandes JC,Martel PJ,Pelletier JP.The role of cytokines in osteoarthritis pathophysiology. Biorheology,2002,39:237-246.
9Evans CH,Ghivizzani SC,Kang R,et al .Gene therapy for rheumatic diseases. Arthritis Rheum, 1999,42:1-16
